Polycythemia Vera-PV 95% JAK2 V617F 1% JAK2 exon 12 4% other Essential Thrombocythemia-ET 50-60% JAK2 20-25% CALR 5-10% MPL 5-25% other Primary Myelofibrosis -PMF 50-60% JAK2 20-30% CALR 5-10% MPL 0-25% other ET: essential thrombocythemia
; PMF:primary myelofibrosis; PV: policytemia vera Note: Table made from pie chart.
Front-line therapy in polycythemia vera and essential thrombocythemia
. Blood Rev 2012; 26(5):205-211.
Efimova et al., "Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia
patients treated with pegylated-interferon alpha and correlation with [JAK2.sup.V617F] allelic burden," Experimental Hematology & Oncology, vol.
Wadenvik, "Diagnostic and differential criteria of essential thrombocythemia
and reactive thrombocytosis," Leukemia & Lymphoma, vol.
(2011) Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia
: a retrospective study.
Impact of Jak2v617f mutational status on phenotypic features in essential thrombocythemia
and primary myelofibrosis.
A prognostic model to predict survival in 867World Health Organization-defined essential thrombocythemia
at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.
(ET) is a clonal expansion of multipotential stem cells.
These present as essential thrombocythemia
(ET) characterized by thrombocytosis, polycythemia vera (PV) with predominant erythrocytosis and concomitant leuko- and thrombocytosis, or myelofibrosis (MF) with expansion of megakaryocytes and reactive bone marrow fibrosis .
[7.] Tefferi A, Wassie EA, Guglielmelli P, et al Type 1 versus type 2 calreticulin mutations in essential thrombocythemia
: A collaborative study of 1027 patients.
(5) Myeloid neoplasms with 3q21q26 anomalies are not only seen in acute myeloid leukemias (AMLs), (6,7) but also in myelodysplastic syndromes (MDS) (5); blast crisis of myeloproliferative neoplasm (MPN), such as chronic myelogenous leukemia (8) or leukemic transformation of essential thrombocythemia
(9); and even in some MDS/myeloproliferative neoplasm cases, such as chronic myelomonocytic leukemia.
Global Markets Direct's, 'Essential Thrombocythemia
- Pipeline Review, H1 2016', provides an overview of the Essential Thrombocythemia